In today's complex clinical development landscape, a successful clinical trial both relies on and generates massive amounts of data. Not always having the technical expertise or related technologies and processes to efficiently transfer large data volumes in a timely manner, sponsors are increasingly turning to external service partners to oversee and manage vital study data transfers. This is especially critical as the industry continues to experience a switching of the hands in terms of drug development acquisitions where data management transfers may need a seamless dataflow whilst upkeeping data quality and integrity.

Recently, a European pharmaceutical sponsor acquired a treatment for the rare disease Cushing's syndrome from the initial developer. IQVIA was selected to oversee the data transition from two active Phase III studies from the original sponsor to the new beneficiary, which included an overhaul of used processes and technologies and team members involved from the sponsors.

Due to existing contractual agreements, IQVIA was given a timeframe of only six months to complete the large volume data transitions for both studies.